183 related articles for article (PubMed ID: 28710496)
1. Dietary geranylgeraniol can limit the activity of pitavastatin as a potential treatment for drug-resistant ovarian cancer.
de Wolf E; Abdullah MI; Jones SM; Menezes K; Moss DM; Drijfhout FP; Hart SR; Hoskins C; Stronach EA; Richardson A
Sci Rep; 2017 Jul; 7(1):5410. PubMed ID: 28710496
[TBL] [Abstract][Full Text] [Related]
2. Identification of foods that affect the anti-cancer activity of pitavastatin in cells.
Jawad MJ; Ibrahim S; Kumar M; Burgert C; Li WW; Richardson A
Oncol Lett; 2022 Mar; 23(3):73. PubMed ID: 35111242
[TBL] [Abstract][Full Text] [Related]
3. Screening a library of approved drugs reveals that prednisolone synergizes with pitavastatin to induce ovarian cancer cell death.
Abdullah MI; Abed MN; Khanim F; Richardson A
Sci Rep; 2019 Jul; 9(1):9632. PubMed ID: 31270377
[TBL] [Abstract][Full Text] [Related]
4. The HMG-CoA reductase inhibitor, simvastatin, exhibits anti-metastatic and anti-tumorigenic effects in ovarian cancer.
Stine JE; Guo H; Sheng X; Han X; Schointuch MN; Gilliam TP; Gehrig PA; Zhou C; Bae-Jump VL
Oncotarget; 2016 Jan; 7(1):946-60. PubMed ID: 26503475
[TBL] [Abstract][Full Text] [Related]
5. Induction of 3-hydroxy-3-methylglutaryl-CoA reductase mediates statin resistance in breast cancer cells.
Göbel A; Breining D; Rauner M; Hofbauer LC; Rachner TD
Cell Death Dis; 2019 Jan; 10(2):91. PubMed ID: 30692522
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of the mevalonate pathway augments the activity of pitavastatin against ovarian cancer cells.
Abdullah MI; Abed MN; Richardson A
Sci Rep; 2017 Aug; 7(1):8090. PubMed ID: 28808351
[TBL] [Abstract][Full Text] [Related]
7. An actionable sterol-regulated feedback loop modulates statin sensitivity in prostate cancer.
Longo J; Mullen PJ; Yu R; van Leeuwen JE; Masoomian M; Woon DTS; Wang Y; Chen EX; Hamilton RJ; Sweet JM; van der Kwast TH; Fleshner NE; Penn LZ
Mol Metab; 2019 Jul; 25():119-130. PubMed ID: 31023626
[TBL] [Abstract][Full Text] [Related]
8. The isomiR-140-3p-regulated mevalonic acid pathway as a potential target for prevention of triple negative breast cancer.
Bhardwaj A; Singh H; Trinidad CM; Albarracin CT; Hunt KK; Bedrosian I
Breast Cancer Res; 2018 Dec; 20(1):150. PubMed ID: 30537987
[TBL] [Abstract][Full Text] [Related]
9. Geranylgeraniol suppresses the viability of human DU145 prostate carcinoma cells and the level of HMG CoA reductase.
Fernandes NV; Yeganehjoo H; Katuru R; DeBose-Boyd RA; Morris LL; Michon R; Yu ZL; Mo H
Exp Biol Med (Maywood); 2013 Nov; 238(11):1265-74. PubMed ID: 24006306
[TBL] [Abstract][Full Text] [Related]
10. Suppression of MET Signaling Mediated by Pitavastatin and Capmatinib Inhibits Oral and Esophageal Cancer Cell Growth.
Xu B; Muramatsu T; Inazawa J
Mol Cancer Res; 2021 Apr; 19(4):585-597. PubMed ID: 33443139
[TBL] [Abstract][Full Text] [Related]
11. Effect of pitavastatin on apolipoprotein A-I production in HepG2 cell.
Maejima T; Yamazaki H; Aoki T; Tamaki T; Sato F; Kitahara M; Saito Y
Biochem Biophys Res Commun; 2004 Nov; 324(2):835-9. PubMed ID: 15474503
[TBL] [Abstract][Full Text] [Related]
12. Pitavastatin slows tumor progression and alters urine-derived volatile organic compounds through the mevalonate pathway.
Wang L; Wang Y; Chen A; Teli M; Kondo R; Jalali A; Fan Y; Liu S; Zhao X; Siegel A; Minami K; Agarwal M; Li BY; Yokota H
FASEB J; 2019 Dec; 33(12):13710-13721. PubMed ID: 31585508
[TBL] [Abstract][Full Text] [Related]
13. Functional interplay between the macrophage scavenger receptor class B type I and pitavastatin (NK-104).
Han J; Parsons M; Zhou X; Nicholson AC; Gotto AM; Hajjar DP
Circulation; 2004 Nov; 110(22):3472-9. PubMed ID: 15557368
[TBL] [Abstract][Full Text] [Related]
14. Pitavastatin calcium: clinical review of a new antihyperlipidemic medication.
Yee LL; Wright EA
Clin Ther; 2011 Aug; 33(8):1023-42. PubMed ID: 21816477
[TBL] [Abstract][Full Text] [Related]
15. Pitavastatin downregulates expression of the macrophage type B scavenger receptor, CD36.
Han J; Zhou X; Yokoyama T; Hajjar DP; Gotto AM; Nicholson AC
Circulation; 2004 Feb; 109(6):790-6. PubMed ID: 14970117
[TBL] [Abstract][Full Text] [Related]
16. Downregulation of survivin expression and elevation of caspase-3 activity involved in pitavastatin-induced HepG 2 cell apoptosis.
Wang J; Xu Z; Zhang M
Oncol Rep; 2007 Aug; 18(2):383-7. PubMed ID: 17611660
[TBL] [Abstract][Full Text] [Related]
17. Pitavastatin: novel effects on lipid parameters.
Chapman MJ
Atheroscler Suppl; 2011 Nov; 12(3):277-84. PubMed ID: 22152282
[TBL] [Abstract][Full Text] [Related]
18. Effect of telmisartan on the therapeutic efficacy of pitavastatin in high-fat diet induced dyslipidemic guinea pigs.
Xu C; Fang D; Chen X; Xinyue L; Nie Y; Xie Y; Ma Y; Deng S; Zhang Z; Song X
Eur J Pharmacol; 2015 Sep; 762():364-71. PubMed ID: 26057693
[TBL] [Abstract][Full Text] [Related]
19. Pitavastatin decreases the expression of endothelial lipase both in vitro and in vivo.
Kojima Y; Ishida T; Sun L; Yasuda T; Toh R; Rikitake Y; Fukuda A; Kume N; Koshiyama H; Taniguchi A; Hirata K
Cardiovasc Res; 2010 Jul; 87(2):385-93. PubMed ID: 20045866
[TBL] [Abstract][Full Text] [Related]
20. Nsc23925 prevents the development of paclitaxel resistance by inhibiting the introduction of P-glycoprotein and enhancing apoptosis.
Yang X; Shen J; Gao Y; Feng Y; Guan Y; Zhang Z; Mankin H; Hornicek FJ; Duan Z
Int J Cancer; 2015 Oct; 137(8):2029-39. PubMed ID: 25904021
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
